It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The human epidermal growth factor receptor 2 (HER2) gene amplification status is a crucial marker for evaluating clinical therapies of breast or gastric cancer. We propose a deep learning-based pipeline for the detection, localization and classification of interphase nuclei depending on their HER2 gene amplification state in Fluorescence in situ hybridization (FISH) images. Our pipeline combines two RetinaNet-based object localization networks which are trained (1) to detect and classify interphase nuclei into distinct classes normal, low-grade and high-grade and (2) to detect and classify FISH signals into distinct classes HER2 or centromere of chromosome 17 (CEN17). By independently classifying each nucleus twice, the two-step pipeline provides both robustness and interpretability for the automated detection of the HER2 amplification status. The accuracy of our deep learning-based pipeline is on par with that of three pathologists and a set of 57 validation images containing several hundreds of nuclei are accurately classified. The automatic pipeline is a first step towards assisting pathologists in evaluating the HER2 status of tumors using FISH images, for analyzing FISH images in retrospective studies, and for optimizing the documentation of each tumor sample by automatically annotating and reporting of the HER2 gene amplification specificities.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 University Hospital Carl Gustav Carus (UKD), TU Dresden, Institute of Pathology, Dresden, Germany
2 Carl Gustav Carus Faculty of Medicine, TU Dresden, Institute for Medical Informatics and Biometry (IMB), Dresden, Germany (GRID:grid.4488.0) (ISNI:0000 0001 2111 7257); TU Dresden, Center for Information Services and High Performance Computing (ZIH), Dresden, Germany (GRID:grid.4488.0) (ISNI:0000 0001 2111 7257)
3 Max Planck Institute of Molecular Cell Biology and Genetics (MPI-CBG), Dresden, Germany (GRID:grid.419537.d) (ISNI:0000 0001 2113 4567); Center for Systems Biology Dresden (CSBD), Dresden, Germany (GRID:grid.495510.c)
4 ASGEN GmbH & Co. KG, Dresden, Germany (GRID:grid.495510.c)
5 University Hospital Carl Gustav Carus (UKD), TU Dresden, Institute of Pathology, Dresden, Germany (GRID:grid.495510.c)
6 Partner Site Dresden, National Center for Tumor Diseases (NCT), Dresden, Germany (GRID:grid.495510.c)
7 Carl Gustav Carus Faculty of Medicine, TU Dresden, Institute for Medical Informatics and Biometry (IMB), Dresden, Germany (GRID:grid.4488.0) (ISNI:0000 0001 2111 7257); Partner Site Dresden, National Center for Tumor Diseases (NCT), Dresden, Germany (GRID:grid.4488.0)
8 University Hospital Carl Gustav Carus (UKD), TU Dresden, Institute of Pathology, Dresden, Germany (GRID:grid.4488.0); Partner Site Dresden, National Center for Tumor Diseases (NCT), Dresden, Germany (GRID:grid.4488.0)